Niflugel (Niflumic Acid)

Niflumic acid works by inhibiting cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the production of prostaglandins that cause inflammation and pain. It also blocks voltage‑gated chloride channels in peripheral nerves, contributing to analgesia. The dual action diminishes swelling, redness and discomfort at the site of application.

The appropriate dose of Niflugel is determined by the prescribing healthcare professional based on the specific condition, severity, patient age and treatment area. No fixed dosing regimen is provided here; patients should follow the instructions given by their prescriber and the product label.

Safety data for topical niflumic acid in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To order Niflugel, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Niflugel contains niflumic acid, a fenamate class NSAID, which offers both cyclooxygenase inhibition and chloride‑channel blockade. Compared with more common topical NSAIDs such as diclofenac or ibuprofen gels, niflumic acid may provide additional analgesic benefit through its unique ion‑channel activity, though clinical choice depends on physician preference, patient tolerance and regulatory availability.

Store Niflugel at room temperature, preferably below 25 °C, in its original packaging. Protect the container from moisture, direct sunlight and extreme temperatures. Keep the product out of reach of children and avoid freezing. If the gel appears discoloured or the seal is broken, discard it.

Apply a thin layer of Niflugel to the clean, dry skin over the affected area, gently massaging until absorbed. For ocular use, follow the specific instructions on the label or as directed by a clinician. Do not cover the treated area with occlusive dressings unless advised, and wash your hands after application.

The most serious risks include severe allergic reactions such as contact dermatitis or anaphylaxis, and systemic NSAID‑related effects like gastrointestinal bleeding, ulceration or renal impairment, especially when used together with other NSAIDs or in patients with pre‑existing kidney disease.

Niflugel should be avoided in individuals with known hypersensitivity to niflumic acid, other fenamates, or any component of the formulation. It is also contraindicated in patients with severe renal or hepatic impairment, active gastrointestinal ulcer disease, or those receiving systemic anticoagulants without medical supervision.